A Phase II Study of JCAR017 in People with Recurrent or Persistent Follicular Lymphoma or Marginal Zone Lymphoma

Share
Print

Full Title

A Phase 2, Open-Label, Single-Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (NHL) (Transcend FL)

Purpose

The purpose of this study is to evaluate the safety and effectiveness of a novel treatment for people with follicular lymphoma or marginal zone lymphoma that has continued to grow or came back despite prior therapy. The treatment involves removing some of a patient’s immune cells called T cells, genetically modifying and growing them in a laboratory, and then returning them to the patient to find and kill lymphoma cells. 

The new modified T cells are called JCAR017 cells and are given back to the patient intravenously (by vein). This approach is a form of immunotherapy.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have follicular lymphoma or marginal zone lymphoma that has continued to grow or came back despite prior therapy.
  • Patients must recover from the serious side effects of previous treatments before entering the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. M. Lia Palomba at 646-608-3711.

Protocol

21-013

Phase

II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators